Clinical features and prognostic analysis of primary hepatic angiosarcoma
10.3760/cma.j.cn113884-20250303-00068
- VernacularTitle:原发性肝血管肉瘤的临床特征与预后分析
- Author:
Maimaitiming NUERSIMANGULI
1
;
Junshuai XUE
1
;
Hong ZHAO
1
;
Jianqiang CAI
1
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院肝胆外科，北京 100021
- Publication Type:Journal Article
- Keywords:
Hemangiosarcoma;
Liver;
Clinical features;
Comprehensive treatment;
Prognosis
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(10):732-736
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics, treatment approaches and prognosis of primary hepatic angiosarcoma (PHA).Methods:Clinical data of 15 PHA patients treated at the Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 2005 and April 2024 were retrospectively analyzed, including three females and 12 males, aged (59.4±11.9) years. Clinical manifestations, tumor characteristics, and survival outcomes were summarized. Kaplan Meier method was used to plot survival curves.Results:The clinical manifestations and tumor markers of the patients were non-specific, and the lesion sizes varied. The diagnosis was confirmed by pathology, and immunohistochemical staining showed positive expression of vimentin, endothelial cell markers CD31, and CD34 in most of the tested patients (seen on 9/11, 8/11, and 7/11, respectively). Patients were followed up for 2-234 months. Eight patients died at the last follow-up. The median overall survival of the patients was 42.37 months, and the cumulative survival rates at 1, 3, and 5 years were 66.7%, 59.3%, and 44.4%, respectively.Conclusion:The clinical features of PHA lack specificity, and diagnosis relies on pathology and immunohistochemistry. Surgical resection remains the treatment of choice. For advanced-staged patients, actively exploring effective comprehensive therapeutic strategies holds promise for extending overall survival.
